MedicaidSeptember 21, 2023
Clinical Criteria updates - June 2023
Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem.
On August 19, 2022, September 12, 2022, February 24, 2023, May 19, 2023, June 12, 2023, and July 11, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Empire BlueCross BlueShield HealthPlus (Empire). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff.
Note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Empire only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised |
October 28, 2023 | *CC-0243 | Vyjuvek (beremagene geperpavec) | New |
October 28, 2023 | *CC-0242 | Epkinly (epcoritamab-bysp) | New |
October 28, 2023 | *CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | New |
October 28, 2023 | CC-0228 | Leqembi (lecanemab) | Revised |
October 28, 2023 | *CC-0061 | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications | Revised |
October 28, 2023 | *CC-0015 | Infertility and HCG Agents | Revised |
October 28, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised |
October 28, 2023 | CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised |
October 28, 2023 | *CC-0177 | Zilretta (triamcinolone acetonide extended-release) | Revised |
October 28, 2023 | CC-0149 | Select Clotting Agents for Bleeding Disorders | Revised |
October 28, 2023 | CC-0032 | Botulinum Toxin | Revised |
October 28, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
October 28, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised |
October 28, 2023 | *CC-0174 | Kesimpta (ofatumumab) | Revised |
October 28, 2023 | *CC-0209 | Leqvio (inclisiran) | Revised |
October 28, 2023 | *CC-0011 | Ocrevus (ocrelizumab) | Revised |
NYBCBS-CD-036882-23-CPN36110
PUBLICATIONS: October 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/new-york/articles/clinical-criteria-updates-june-2023-8-15631
Or scan this QR code with your phone